Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by National Cancer Institute (NCI).
Recruitment status was Recruiting
Information provided by:
National Cancer Institute (NCI)
First received: August 26, 2009
Last updated: April 20, 2010
Last verified: August 2009
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at tissue samples from patients with glioma or other brain tumors.
Brain and Central Nervous System Tumors
Other: laboratory biomarker analysis
Other: pharmacogenomic studies
||Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis
Primary Outcome Measures:
- Pathophysiology of gliomas and identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||December 2008 (Final data collection date for primary outcome measure)
- To better understand the pathophysiology of gliomas and identify molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches.
- To compare gene expression profiles, in terms of response to treatment, and attempt to isolate subgroups of patients with objective response to certain types of chemotherapy or radiotherapy.
OUTLINE: This is a multicenter study.
Biological samples are collected from patients at time of surgery for diagnostic and/or treatment purposes.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- No urgent situation
- No known or suspected active infection
- Must not be deprived of liberty or protected by law
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
- No concurrent participation in other trials that require a period of exclusion
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00967200
|Montpellier, France, 34295 |
|Contact: Luc Bauchet, MD Not Available |
|Clinique Gui de Chauliac
|Montpellier, France, 34295 |
|Contact: Luc Bauchet, MD 33-67-542-494 |
University Hospital, Montpellier
||Luc Bauchet, MD
||University Hospital, Montpellier
No publications provided
History of Changes
|Other Study ID Numbers:
||CDR0000626732, CHUM-DGS-2003/0402, CHUM-UF7745, INCA-RECF0467
|Study First Received:
||August 26, 2009
||April 20, 2010
Keywords provided by National Cancer Institute (NCI):
adult pilocytic astrocytoma
adult anaplastic astrocytoma
adult diffuse astrocytoma
adult giant cell glioblastoma
adult pineal gland astrocytoma
adult subependymal giant cell astrocytoma
adult brain stem glioma
adult choroid plexus tumor
adult supratentorial primitive neuroectodermal tumor (PNET)
adult anaplastic ependymoma
adult myxopapillary ependymoma
adult meningeal hemangiopericytoma
adult grade I meningioma
adult grade II meningioma
adult anaplastic meningioma
adult papillary meningioma
adult anaplastic oligodendroglioma
adult mixed glioma
recurrent adult brain tumor
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 26, 2014
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Central Nervous System Diseases
Nervous System Diseases
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue